Miltefosine

Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.
Miltefosine is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of cutaneous, mucosal, and visceral leishmaniasis in patients >12 years of age.
  • Miltefosine no longer needs to be obtained through the CDC.

NON-FDA APPROVED USES

  • Treatment of free-living amoeba, including primary meningoencephalitis (PAM) caused by Naegleria fowleri and granulomatous amebic encephalitis (GAM) caused by Balamuthia mandrillaris and Acanthamoeba species.
  • Use in combination with voriconazole and terbinafine for the management of Scedosporium prolificans

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of cutaneous, mucosal, and visceral leishmaniasis in patients >12 years of age.
  • Miltefosine no longer needs to be obtained through the CDC.

NON-FDA APPROVED USES

  • Treatment of free-living amoeba, including primary meningoencephalitis (PAM) caused by Naegleria fowleri and granulomatous amebic encephalitis (GAM) caused by Balamuthia mandrillaris and Acanthamoeba species.
  • Use in combination with voriconazole and terbinafine for the management of Scedosporium prolificans

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: September 3, 2019